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The Treatment of Acute Stroke
Irina Alexandrovna Savvina and Anna Olegovna Petrova
Abstract
Stroke is a major public health issue, because of its high incidence rate, high case
fatality rate, risk of residual physical and neuropsychological disabilities, and direct
and indirect costs. Many strokes are preventable and treatable in the acute stage,
provided that patients are admitted soon enough. The term stroke covers a wide
range of heterogeneous disorders, depending on the severity of the clinical presen-
tation, from transient deficits to severe cases with coma and early death; the
underlying mechanism, i.e., cerebral ischemia, parenchymal hemorrhage, subdural
hemorrhage, or subarachnoid hemorrhage (SAH); and the cause, i.e., atherosclero-
sis, cardioembolism, small-vessel occlusion, rare vasculopathies and undetermined
causes in cerebral ischemia, or vascular malformations, cerebral amyloid
angiopathies, small-vessel diseases, rare vasculopathies and undetermined causes in
parenchymal hemorrhages. This chapter will focus only on acute cerebral ischemia
and parenchymal hemorrhage. We will cover the general assessment of stroke
patients, the complications that can occur in the acute stage, the treatment of acute
stroke, and finally a few situations that require specific managements and where
evidence-based data are scarce.
Keywords: cerebral ischemia, parenchymal hemorrhages, thrombolytic therapy,
complications
1. Introduction
This chapter focuses on the treatment of acute cerebral ischemia and intracranial
hemorrhage, which are two types of stroke. Stroke is characterized by a sudden loss
of brain function with no established cause other than vascular origin. This applies
to both ischemic stroke and intracranial hemorrhage.
1.1 The diagnosis of stroke
Acute stroke suggests the following signs:
• Sudden onset of symptoms and development of the clinical picture in a few
seconds or minutes with further stabilization or improvement.
• Focal neurological symptoms associated with damage to certain parts of the
brain: motor deficits (weakness or immobility of the limbs on one side of the
body (hemiplegia or hemiparesis) or an isolated limb), loss of sensitivity
(decreased sensitivity in various parts of the body), aphasia, agnosia, and
vision disorders.
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• Symptoms suggesting a loss of function: limb tremors, convulsions,
paresthesias, visual hallucinations, and flashes before the eyes.
• Headache, nausea and vomiting, dysphagia, dysarthria, dysphonia, diplopia,
ataxia, hiccups, one-sided acute hearing loss, respiratory disorder, convulsive
syndrome, and transient loss of consciousness may be clinical manifestations of
a stroke localized in the brain stem.
• Symptoms such as loss of consciousness, dizziness, general weakness,
confusion, urinary incontinence, syncopal condition, and tinnitus do not
indicate the development of a stroke if they are not associated with focal
neurological symptoms.
For the differential diagnosis of ischemic and hemorrhagic strokes, it is
necessary to conduct a neuroimaging study [1]. This is the most important stage of
diagnosis, because patients with ischemic and hemorrhagic strokes require
different therapies in the acute period and various measures of secondary
prevention [2].
Magnetic resonance imaging (MRI) is the most appropriate diagnostic method for
patients with acute cerebral circulation disorders due to the following reasons [3]:
1.T1- and T2-weighted images and fluid-attenuated inversion recovery (FLAIR)
sequences allow the differentiation of old foci and foci of nonvascular origin.
2.Diffusion-weighted images allow the identification of new ischemic foci. Low
brain blood flow causes the development of cytotoxic cell edema and, as a
result, a decrease in the movement of extracellular fluid, which is displayed as
a hyperintensive signal on diffusion-weighted images, and a decrease in the
water diffusion coefficient. These changes appear earlier than changes in T1
and T2 and FLAIR.
3.T* sequences are used to detect hemorrhages.
4.Time-of-flight (TOF) MR angiography can be used to visualize the occlusion
of extra- and intracranial arteries.
When MRI is not available in an emergency or cannot be performed due to
contraindications (established rhythm driver, claustrophobia, psychomotor agita-
tion), an emergency computed tomography (CT) scan of the brain is performed
without contrast. CT scan reveals an intracranial hemorrhage in the form of a
hyperintensive zone in the brain parenchyma. Figure 1 shows a non-contrast CT
scan with a spontaneous hyperdensity of the right cerebral hemisphere, due to a
deep intracerebral hemorrhage (ICH). In the early stages of acute cerebral ischemia,
CT signs of ischemia may be absent. But within 3 hours, you can see signs of
ischemia, for example, the disappearance of a clear border of gray and white matter.
With the occlusion of the middle cerebral artery, CT signs will appear in the form of
a hyperintensive zone. CT with contrast allows you to visualize the anatomy of the
arteries and perfusion.
The most common causes of ischemic stroke are common atherosclerosis, atrial
fibrillation (AF), occlusion of small perforating arteries of the brain, pathology of
heart valves, and infectious diseases, in young patients—cerebral artery dissection.
Intracerebral hemorrhages in most cases are the result of the damage to small
cerebral vessels due to chronic arterial hypertension or amyloid angiopathy.
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1.2 Examination of patients with acute stroke
For all patients in the acute stage, the following examinations should be carried
out, which will determine the treatment plan: a thorough collection of anamnesis to
determine the presence of hypertension, medications used, alcohol abuse, and sub-
stance abuse and a family history of stroke, oncology, and trauma; a clinical exam-
ination; blood test to detect polycythemia and plateletemia, erythrocyte
sedimentation rate (ESR) to detect vasculitis, and the level of glycemia to detect
diabetes or hypoglycemia, and coagulation tests. Cardiac assessment including
electrocardiogram (ECG) and echocardiography (EchoCG) is quite important in all
cases and Holter in selected cases. ECG recording to detect heart attacks, atrial
fibrillation, continuous ECG monitoring to detect arrhythmias; monitoring of sys-
tolic, diastolic, and mean blood pressure (BP) by noninvasive method;
dopplerography to detect stenoses and dissections of cervical and intracranial ves-
sels; transthoracic EchoCG to detect blood clots, tumors, valve pathology, vegeta-
tions on the valves, reduction of ejection fraction, and the presence of an open oval
window. Neuroimaging methods include MRI and CT of the brain to detect caverns,
intracranial venous thromboses, cerebral microhemorrhages, arteriovenous
malformations (AVM), tumors, and indirect signs of unknown injuries. Additional
examinations are prescribed depending on the initial results obtained, the patient’s
age, and the presumed etiology of the stroke: angiography (usually MR, CT angiog-
raphy) and specific biological tests when it comes to specific causes, such as anti-
nuclear antibodies, etc.
There are neurological complications that occur in the acute phase of stroke in
any type in the form of convulsive syndrome; hyper- and hypoactive delirium,
especially with a pre-existing decrease of cognitive functions and the development
of metabolic or infectious complications; as well as intracranial hypertension.
Nonspecific complications include bedsores, pneumonia, urinary tract infection,
hyponatremia due to inadequate secretion of antidiuretic hormone (ADH), deep
vein thrombosis, and pulmonary thromboembolism. They are more likely to
Figure 1.
Non-contrast CT scan shows a spontaneous hyperdensity of the right cerebral hemisphere.
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develop in patients with severe neurological deficits. Hyponatremia is a common
accompaniment during the acute stage of stroke. Its relevance to the clinical pre-
sentation, treatment and prognosis should be mentioned.
1.2.1 Protocol of hypernatremia correction in patients with stroke
Hypernatremia: Na >145 mmol/l (the main reason—central DI)
Criteria: polyuria: rate of diuresis >3 ml/kg/hour
Hypernatremia: >145 mmol/l
Urine specific gravity: <1005
Infusion therapy:
Base 75–100 ml/hour monitoring of sodium concentration every 6 hours.
Fluid deficit replenishment: in case of polyuria—compensation of fluid loss.
If ineffective, symptoms of diabetes insipidus (DI) persist—ADH
Desmopressin: 2–4 mcg per 24 hours
Vasomirin (nasal spray): 10 mcg
1.2.1.1 Fluid loss calculation
Total body fluid = 0.6  body weight
Free water deficit = (0.6  body weight)  (0.6 body weight)  (140/Na act)
Example: body weight = 75 kg, Na = 154 mmol/l
Free water deficit = 0.6  75  [0.6  75  (140/154)] = 45  40.9 = 4.1 l
1.2.2 Protocol of hyponatremia correction in patients with stroke
Hyponatremia: Na < 135 mmol/l
If Na <125 mmol/l, there is a high risk of neurological disorders.
1.Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
A.No neurological deterioration
B. Acute neurological deterioration
• Hyponatremia: no longer than 24 hours acute not prolonged
reducing the level of sodium
• Negative fluid balance: IV 3% NaCl—4 ml/kg during 15–30 min
• 2/3 of physiological need for fluid + furosemide 1 mg/kg
• Intravenous (IV): only sodium solutions
• Monitoring: fluid balance, diuresis, sodium in plasma/urine, and
urine specific gravity
2.Central salt wasting syndrome
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A.Restoring of fluid deficit
B. Positive sodium balance
C. Rehydration
D.HyperHAES: 0.25 ml/kg/hour or 0.9%NaCl
E. Fludrocortisone: 0.4 mg per 24 hours
F. Acute hyponatremia correction rate (<48 h): ≤24 mmol/l/24 hours
G.Chronic hyponatremia correction rate (>48 h): ≤0.5 mmol/l/hour, but
≤10 mmol/l/24 hours
H.In the presence of an accompanying potassium deficit: ≤4 mmol/l/
25 hours
2. Treatment of acute stroke
2.1 General principles of the therapy
Stroke patients should be treated in specialized departments. For every 24
patients treated in a specialized rather than general ward, one death and one dis-
ability are prevented [4]. This does not depend on the age, type, and severity of
stroke [4, 5]. Therefore, specialized departments are very important for the treat-
ment of stroke patients [1, 4]. For all strokes with persistent neurological deficits,
the treatment aimed at stabilizing the patient’s condition, controlling vital func-
tions, and actively curating problems that may worsen recovery is indicated. This is
the main component of the stroke treatment program [6, 7].
In the detection and treatment of emergency life-threatening conditions (risk of
aspiration, epileptic status, respiratory failure, etc.), the patency of the upper
respiratory tract should be ensured in the case of deprivation of consciousness to the
level of coma, respiratory failure of central origin, or local causes leading to respi-
ratory disorders.
The stabilization of most physiological parameters, blood pressure, saturation
(more than 93%), glycemic level (less than 180 mg), body temperature (below
37.50°C), and hydration, is necessary in the first few days to prevent negative
dynamics in the penumbra zone.
A normal respiratory function with adequate blood oxygenation is necessary in
the acute period of stroke to maintain an adequate oxygen delivery to brain cells,
but there is no conclusive evidence that all patients with stroke receive oxygen
therapy with a positive result [4]. In cases of hypoxemia, improved blood oxygen-
ation is achieved by oxygen therapy via a nasal catheter and noninvasive or invasive
ventilation.
Complications of acute stroke include neurogenic stressful cardiomyopathy,
paroxysmal sympathetic hyperactivity, atrial fibrillation, acute heart failure, myo-
cardial infarction, and sudden death [1, 2]. The frequency of these complications
explains the need for a constant monitoring for 2–3 days.
Many stroke patients are in a state of dehydration, which leads to a worse
outcome of the disease [1, 2]. Despite limited clinical data, the administration of
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infusion therapy (0.9% sodium chloride solution) is considered part of the overall
treatment of stroke, especially in patients with an increased risk of dehydration due
to depression of consciousness or respiratory disorders. Experience in the treatment
of hyperglycemia recommends avoiding the introduction of glucose solutions in the
early period of stroke and strict control of the level of glycemia [4].
According to the literature, there are no mechanisms for autoregulation of cere-
bral blood flow in the penumbra zone. Therefore, a decrease in blood pressure in the
first hours after a stroke before the penumbra zone appears can cause significant
hypoperfusion, which worsens the development of the ischemia zone. Therefore, in
the acute period, it is not necessary to aggressively treat arterial hypertension if
there are no concomitant life-threatening conditions, such as aortic dissection or
intracranial hematoma [2, 4].
In practice, blood pressure correction is usually started when the systolic blood
pressure exceeds 220 mm Hg and diastolic blood pressure exceeds 120 mm Hg.
However, in many clinics, antihypertensive therapy is performed only in cases of
heart failure, acute renal failure, aortic arch dissection, or malignant hypertension.
When conducting a thrombolytic therapy (TLT), it is common practice to maintain
blood pressure below 185 mm Hg. The intravenous administration of labetalol
(10 mg bolus, followed by an infusion of 0.1–0.3 mg/kg/hour) or urapidil (12.5 mg
bolus for 20 seconds, followed by an infusion of 6–30 mg/hour) is often used.
Hyperglycemia occurs in 60% of stroke patients who have not previously suf-
fered from diabetes [2, 7]. Hyperglycemia after a stroke is usually associated with a
large volume of infarction and cortical damage and is associated with an adverse
outcome of the disease [4]. Currently, the routine use of insulin infusions in
patients with moderate hyperglycemia is not recommended. The European Stroke
Association recommends maintaining glycemia below 180 mg/dl (10 mmol/l) [4].
Body temperature control: hyperthermia is associated with an increase in the size of
the infarction zone and a worsening of the outcome of the disease [8]. Fever is
associated with a worse clinical outcome [9]. When the body temperature increases,
it is necessary to quickly exclude concomitant infections and, if necessary, treat them.
2.1.1 Prevention of acute stroke complications
The prevention of trophic disorders in the form of bedsores is carried out by
establishing an early enteral nutrition through a nasogastric probe with an adequate
calorie of nutritional mixtures: early mobilization, anti-bedsore mattresses, suitable
beds, and nursing care.
Aspiration pneumonia: diagnosis of dysphagia (special examination of the func-
tion of swallowing by doctors, nurses, or speech therapists) [10, 11] or use of a
nasogastric probe if necessary.
Deep vein thrombosis and pulmonary embolism: low-molecular-weight heparins
(LMWH) in prophylactic doses reduce the risk of thromboembolic complications
without affecting mortality [2]. Their use slightly increases the risk of intracranial
hemorrhages. The use of LMWH is recommended only if the patient has risk factors
for deep vein thrombosis and pulmonary embolism, such as lower limb immobili-
zation, in the first few hours after a stroke [2], and not earlier than 24 hours in
patients with intracranial hemorrhage [9]. A recent study of Clots in Legs Or
sTockings after Stroke (CLOTS) [12] has shown that an intermittent pneumatic
compression reduces the risk of deep vein thrombosis and can improve stroke
survival in patients who cannot go to the toilet with an assistant.
Rehabilitation: it is an important issue both in acute phase and in chronic phase.
Points to be covered are position turning to avoid pressure sores, chest physiother-
apy to minimize lung complication, swallowing assessment and training, limb
movements to prevent deep vein thrombosis, speech therapy, early mobilization,
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etc. All should be started as early as possible. Rehabilitation should begin as soon as
the patient’s condition stabilizes: passive measures to minimize contractures, bed-
sores, and pneumonia. A coordinated multidisciplinary approach to patient man-
agement with the help of constantly trained staff is important, which leads to a
reduction in mortality and disability.
2.2 Thrombolytic therapy
The intravenous administration of a recombinant tissue plasminogen activator
(tPA) increases the chances of a favorable outcome approximately 8 times within
3 months if performed in the first 90 minutes, 2 times when performed within 91–
180 minutes after a stroke, and 1.4 times when performed in 181–270 minutes [6, 13].
The mortality does not change when administered up to 270 min after stroke onset,
but increases with later administration of tPA [6]. Indications and contraindications
for thrombolytic therapy are noted in Tables 1 and 2, respectively.
Hemorrhagic transformation is more often observed in patients with large
strokes and of old age [7]. The earlier the tPA is introduced, the more likely the
beneficial effect is, and despite the fact that the probability of a favorable effect is
also present when used later than 3 hours from a stroke, it is significantly reduced.
The dose is 0.9 mg/kg (10% intravenous bolus, 90%—within an hour microjet). In
Japan, the recommended dose is lower—0.6 mg/kg. Thus, thrombolytic therapy is
recommended as early as possible after the onset of a stroke, no later than 4.5 hours.
Restrictions apply both to contraindications [increased risk of hemorrhage, delay of
more than 4.5 hours, blood pressure (BP) above 185 mm Hg, blood glucose above
4 G/l] and strict rules of use (only by a doctor trained in the management of stroke
patients and only in the stroke department) [6].
Other ways to achieve rapid recanalization are currently being investigated and
do not change the existing recommendations: other thrombolytic drugs, MRI
patient selection criteria, intra-arterial thrombolytic therapy, and ultrasound-
assisted intravenous thrombolysis. Mechanical thrombextraction is considered a
promising technique in addition to intravenous thrombolysis in patients with
proximal occlusions. In patients receiving oral anticoagulants, mechanical
thrombectomy is often the only recommended recanalization strategy.
2.3 Antithrombotic therapy
Aspirin at a starting dose of 300 mg and then 75–150 mg daily prevents 9 cases of
disability and death per 1000 patients. Aspirin should be prescribed 24 hours after
any thrombolytic therapy. Recently, a Clopidogrel in High-Risk Patients with Acute
Nondisabling of Cerebrovascular Events (CHANCE) study showed that patients
with small strokes and transient ischemic attack (TIA) who received a loading dose
of clopidogrel for 24 hours, against the background of aspirin, and then for 90 days
on 75 mg of aspirin and 75 mg of clopidogrel had better outcomes without the risk of
bleeding.
No. of wording
1. Stroke, ischemic type
2.The time from the symptoms onset to the thrombolysis procedure less than 4.5 hours
3.Age from 18 years and older (after 80 years with caution, individual decision about TLT, taking into
account the perceived risk)
Table 1.
Indications for thrombolytic therapy.
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Low-molecular-weight heparins do not have advantages, because a decrease in
the frequency of early recurrent strokes is balanced by an increase in the frequency
of hemorrhagic transformations. There is no reason to recommend heparin in the
acute stage of ischemic stroke, even in patients with atrial fibrillation.
2.4 Hypothermia and neuroprotection
Experimental studies have shown that potential neuroprotectors are effective,
but this is not confirmed in the human population. Many neuroprotective agents
have been developed based on a cascade of biochemical events leading to cell death.
No. of wording
Cerebral
1.Neuroimaging (CT, MRI) signs of intracranial hemorrhages, brain tumors
2.Hemorrhagic stroke or stroke of an unspecified nature in the anamnes
3. Rapid improvement or mild symptoms by the time of the beginning of TLT (non-invalidizing symptoms) in the
absence of data for occlusion of the main vessels
4. Signs of a severe stroke: clinical [score on the National Institutes of Health Stroke Scale (NIHSS) > 25),
neuroimaging (based on CT of the brain and/or MRI of the brain in the diffusion-weighted imaging (DWI) mode,
the focus of ischemia extends to the territory of a larger basin medium cerebral artery (MCA)]
5. Convulsions at the beginning of a stroke (if there is reason to assume that focal symptoms are represented by
Todd’s paresis)
6. Previous stroke or severe traumatic brain injury within 3 months
7. Suspected subarachnoid hemorrhage (SAH)
8. Surgical intervention on the brain or spinal cord in the anamnesis
Cerebral and somatic
9.Arterial aneurysms, defects in the development of arteries or veins
10. Tumors with a high risk of bleeding
Somatic
11.Hypersensitivity to any component of the drug
12.Hemorrhagic diathesis
13.Arterial hypertension over 185/110 mm Hg or necessity in intensive reduction of less than these figures
14. Bacterial endocarditis, pericarditis
15.Gastrointestinal or urogenital bleeding during the last 3 weeks. Confirmed exacerbations of peptic ulcer disease of
the stomach and duodenum during the last 3 months
16. Liver failure (cirrhosis, active hepatitis, portal hypertension)
17.Acute pancreatitis
18. Present bleeding or extensive bleeding in the recent 6 months
19. Extensive surgery, trauma, delivery, puncture of large vessels, cardiopulmonary resuscitation within the last
10 days
20. Recent myocardial infarction
21. Pregnancy
22.Data on bleeding or acute injury (fracture) at the time of examination
Laboratory
23. Taking indirect anticoagulants (warfarin) if international normalized ratio (INR) >1.3
24.Use of heparin for 48 hours with increased activated partial thromboplastin time (aPTT)
25. Thrombocytopenia less than 100,000/mm3
26.Glycemia less than 2.8 and more than 22.5 mmol/l
27.With previous administration of new oral anticoagulants (dabigatran, rivaroxaban, apixaban), indicators of aPTT,
INR, quantity of platelets, thrombin time, or Xa factor activity should be within normal values. In the absence of
the ability to determine the laboratory data, the last intake of a drug from the oral anticoagulant group should be
>2 days before the development of stroke (with normal kidney function)
28.Other diseases or conditions with increased risk of bleeding or other complications of TLT (the decision is made
by the council of physicians)
Table 2.
Contraindications for thrombolytic therapy.
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We report below the current clinical status of drugs that have been developed as
neuroprotective agents (Table 3) [14].
Hypothermia is a potential opportunity to provide neuroprotection, but due to
side effects and the need for intensive therapy, it can only be used in severe cases,
especially in patients with malignant heart attacks, and currently requires random-
ized trials [8, 15].
2.5 Decompressive neurosurgery
Decompressive neurosurgery (hemispherectomy) reduces mortality and dis-
ability in patients younger than 60 years old who recently suffered a massive stroke
Category,
mechanism
Drug name, name of multicenter
study, and its results
Category,
mechanism
Drug name, name of
multicenter study, and
its results
Ca2+ channel
blocker
Nimodipine: no benefit (VENUS) Noncompetitive
NMDA
antagonist
Dizocilpine, discontinued
Dextrorphan, no benefit
Na+ channel
blocker
Lifarizine, no benefit; lubeluzole, no
benefit; fosphenytoin, discontinued
Competitive
NMDA
antagonist
Selfotel: discontinued
GABA agonist Clomethiazole: no effect AMPA/KA
receptor
antagonist
NBQX, discontinued
YM872, RCT
Free radical
scavenger
Edaravone, clinical use; ebselen, phase
III; NXY059: phase III; tirilazad,
discontinued
Metabotropic
receptor
antagonist
Groups I, II, and III: RCT
being planned
Growth factor bFGF: abandoned AX200 (filgrastim,
G-CSF analogue), phase II
LMWH-CoA
reductase
inhibitor
Lovastatin, phase II;
simvastatin, phase III
Growth
factors,
oxygen
delivery
Human chorionic gonadotropin
(hCG)/erythropoietin (Ntx-265):
phase II
Hemodiluting
agent
Albumin: phase III
(ALIAS)
Ganglioside No benefit Membrane
stabilizer
Citicoline (CDP choline):
phase III
MgSO4 FAST-MAG: ongoing (IMAGE) Iron chelator Deferoxamine mesylate:
phase II
Opioid
receptor
antagonist
Nalmefene: no benefit Metal ion chelator DP-b99: phase III
Polyamine
receptor
antagonist
Eliprodil: discontinued Antibiotic,
pleiotropic
protective effects
Minocycline: phase III
Glycine
antagonist
ACEA-1021, no benefit; gavestinel, no
benefit
Others Piracetam: phase III
VENUS, very early nimodipine use in stroke; NMDA, N-methyl-D-aspartic acid; GABA gamma-aminobutyric acid;
AMPA, amino-hydroxy-methyl-isoxalone propionic acid; KA, kainate; NBQX, 2,3dihydroxy-6-nitro-7-sulfamoyl-
benzo [f]quinoxaline-2,3-dione; RCT, randomized controlled trial; bFGF basic fibroblast growth factor; ALIAS,
albumin in acute stroke; FAST-MAG, Field Administration of Stroke Therapy—Magnesium; ACEA-1021, 5-nitro-
6,7-dichloro-1,4dihydro-2,3-quinoxalinedione.
Table 3.
Neuroprotective drugs developed so far and results of clinical trials.
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in the middle cerebral artery basin [16]. In order to be effective, the operation must
be performed before the development of a malignant brain attack. The best selec-
tion criterion is the volume of damage on a diffusion-weighted MRI within
24 hours; a volume greater than 145 cm3 is a good predictor of malignant infarction.
Therefore, the best candidates for surgical treatment are patients younger than
60 years with a lesion volume of more than 145 cm3 on diffusion-weighted MRI
(6.50). The effectiveness of hemispherectomy is great—every second death is
prevented. Results of the Decompressive Surgery for the Treatment of Malignant
Infarction of the Middle Cerebral Artery II (DESTINY II) study also showed
effectiveness in patients over 60 years of age [3].
3. Treatment of intracranial hemorrhage
It is necessary to control blood pressure (BP). Lowering blood pressure in the
first hours can prevent or slow down the growth of hematoma, as well as reduce the
risk of repeated hemorrhage.
An early decrease in blood pressure can cause cerebral ischemia in low-perfused
and hypometabolic regions of the brain adjacent to the hematoma.
European recommendations are based on the evidence of a low level of signifi-
cance (class 4) [9]:
• No specific drug is recommended.
• In patients with a history of primary arterial hypertension or signs (ECG,
changes in the fundus vessels) of chronic hypertension, systolic pressure above
180 mm Hg or diastolic pressure above 105 mm Hg and in patients without a
history of hypertension, the target blood pressure is 170/100 or average
125 mm Hg.
• In patients without a history of arterial hypertension (systolic blood pressure
above 160 mm Hg and/or diastolic blood pressure above 95 mm Hg), the target
blood pressure is 150/90 mm Hg or BP mean 110 mm Hg.
• Avoid lowering blood pressure by more than 20%. These targets should be
revised for patients who are being monitored for intracranial pressure (ICP)
and are experiencing intracranial hypertension in order to maintain adequate
cerebral perfusion pressure (greater than 70 mm Hg).
The INTERACT 2 study recently showed that in patients with intracerebral
hematoma, an intensive reduction in blood pressure with targets below 140 mm Hg
within an hour slightly improves the outcome and is well tolerated by the patient.
3.1 Prevention of deep vein thrombosis and pulmonary embolism
In patients with intracerebral hematoma, complications such as deep vein
thrombosis and pulmonary embolism are feared. A small study conducted on
patients with intracerebral hematoma showed that the use of intermittent pneu-
matic compression is more effective than the use of compression knitwear alone
[17]. The CLOTS study [12] showed that the use of compression knitwear is inef-
fective, but only 232 patients with intracerebral hematoma were included out of
2518 stroke patients. The expediency of using heparin and low-molecular-weight
heparins is justified only in cases where the probability of bleeding risk is less than
10
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the possible benefit of prescribing drugs. In clinical practice, low doses of fraction-
ated or low-molecular-weight heparin can be prescribed after 24 hours [16].
According to the results of the CLOTS 3 study [12], intermittent pneumatic com-
pression is effective.
3.2 Intracranial hypertension
ICP negatively affects the functional outcome. The superiority of invasive ICP
monitoring over clinical observation and neuroimaging has not been proven. Ways
to reduce ICP by medication help to buy time to prepare for surgical decompres-
sion, if it is planned. In the acute phase of intracranial hemorrhage, it is
recommended to avoid corticosteroids. These recommendations are based on low
confidence data. For the medical treatment of ICH, glycerol, mannitol, HAES, and
short-term hyperventilation (confidence class 4) are used. For example, mannitol
(20%) at a dose of 0.75–1.0 g/kg can be administered as an intravenous bolus
followed by 0.25–0.5 g/kg every 3–6 hours, depending on the neurological status
and fluid balance.
3.3 Intracranial hemorrhage in patients receiving oral anticoagulants
In the acute stage, every patient with intracranial hemorrhage and an INR
greater than 1.4 should receive intravenous vitamin K and drugs that replace the
deficiency of clotting factors, despite the reason for taking oral anticoagulants
(including patients with artificial valves). The goal is to prevent the growth of
hematoma volume. In European protocols, it is recommended to use a concentrated
prothrombin complex or SPP together with the intravenous administration of vita-
min K [18]. Doses of concentrated prothrombin complex: 10–20 U/kg, if the INR is
less than 3.5; or 20–30 units/kg, if the INR exceeds 3.5; together with 10 mg of
vitamin K in/B.
Recombinant factor VIIa is not recommended for routine use outside of
clinical trials.
There is currently no antidote for patients with intracranial hematoma receiving
new oral anticoagulants. This limits the use of these drugs.
There are no specific recommendations for the treatment of hemorrhage on the
background of antiplatelet drugs. Studies of the use of thrombosis have not proved
its effectiveness [6, 13].
3.4 Thrombolytic therapy
In patients with intracranial hemorrhage with increased ventricles and obstruc-
tion of the third and fourth ventricles, according to some data, it is recommended to
use a recombinant tissue plasminogen activator inserted directly into the ventricu-
lar system, which can improve the functional outcome [9].
3.5 Neurosurgical intervention
The removal of a blood clot should be considered in cases where there is neuro-
logical dysfunction or neuroimaging data about occlusion of cerebrospinal fluid
spaces subtentorially. According to European recommendations, ventricular drain-
age and hematoma removal should be performed when the size of the hematoma is
more than 2–3 cm in diameter or in the presence of hydrocephalus, even if the
favorable outcome is doubtful due to old age or coma.
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Dynamic monitoring and conservative medical treatment are the first stage in
the treatment of patients with intracranial hematoma. A special analysis of sub-
groups from the STICH study and a recent meta-analysis showed that craniotomy
should be considered as a treatment option in cases of depression of consciousness
(from 12 to 9 points on the Glasgow scale) [19] or in cases of superficial intracranial
hemorrhage (less than 1 cm from the surface and does not reach the basal ganglia)
[20–22]. With deep-seated hematomas, craniotomy does not bring a positive result.
The STICH II study showed that early surgical treatment did not increase mortality
and disability within 6 months, but slightly improved survival in patients with
spontaneous intracranial hemorrhage in the absence of intraventricular
hemorrhage.
4. Specific clinical situations
4.1 Treatment of stroke due to sinus thrombosis
Sinus thrombosis is the cause of approximately 1% of strokes. It occurs due to
the occlusion of the venous sinuses and/or cortical veins. This can lead to a venous
infarction with petechial hemorrhages or a perivascular venous infarction. Usually,
the cause of sinus thrombosis is congenital and acquired prothrombotic disorders,
such as pregnancy and infections, including infections of the central nervous system
as well as ear, sinuses, mouth, face, or neck. Also the predisposing factors are
various diagnostic and therapeutic procedures, such as surgery, lumbar puncture,
jugular vein catheterization, and administration of certain medications,
especially oral contraceptives, hormone replacement therapy, steroids, and
antitumor drugs [23].
The clinical picture may be different, but sinus thrombosis should be excluded
in young patients with recent headache and stroke-like symptoms, transient neuro-
logical deficits, convulsions, or lobar intracranial hemorrhages. This is especially
true for patients with intracranial hypertension and patients with signs of hemor-
rhagic infarctions, especially if they are numerous and correspond to certain vascu-
lar pools.
The gold standard for diagnosing sinus thrombosis is MRI, which provides direct
visualization of occluded veins, sinuses, and blood clots [23]. Sometimes CT is used
for diagnostics, but if MRI is available, this is not the method of choice for diagnos-
tics. On CT, you can see a hyperintensive shadow of a blood clot in the occluded
sinus, the so-called cord symptom.
4.1.1 Heparin therapy
The available research data on the treatment of venous thrombosis recommend
the use of heparin, as it reduces the risk of death and severe disability without the
risk of intracranial hematoma. It has been shown that anticoagulant therapy leads to
an absolute reduction in the risk of death and disability by 13% and a relative
reduction in the risk by 54%, as well as a positive effect of using heparin without
increasing the risk of intracranial hemorrhage.
According to European recommendations [18], venous thrombosis should be
treated with low-molecular-weight heparins subcutaneously or intravenous
heparin; doses are selected by body weight. The presence of intracranial hemor-
rhage accompanying venous thrombosis is not a contraindication to a heparin
therapy [18].
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4.1.2 Thrombolytic therapy
There is no data from randomized controlled trials on the efficacy and safety of
systemic or local thrombolytic therapy in patients with cerebral vein thrombosis
and sinus thrombosis. A recently published systematic review of thrombolytic
therapy in patients with cerebral vein thrombosis and sinus thrombosis suggests a
favorable effect in comatose patients [24].
According to European protocols [18], there is insufficient data to recommend
the use of systemic or local thrombolytic therapy in patients with cerebral vein
thrombosis and sinus thrombosis. Thrombolytic therapy may be an option if the
patient’s condition worsens despite an adequate anticoagulant therapy.
4.1.3 Oral anticoagulants
After the acute phase, they switch to oral anticoagulant therapy. The Target INR
is 2.0–3.0. In cases of cerebral vein thrombosis and sinus thrombosis during preg-
nancy, oral anticoagulants are not prescribed due to their possible teratogenic
effects and the ability to penetrate the placenta. In these cases, anticoagulant ther-
apy is continued with heparin. There is no available data from controlled studies
concerning the optimal duration of anticoagulant therapy in patients with cerebral
vein thrombosis and sinus thrombosis. MRI data from 33 patients showed that
recanalization occurs within 4 months after cerebral vein thrombosis and sinus
thrombosis, regardless of further anticoagulation therapy [25].
According to European protocols [18], anticoagulants can be prescribed for
3 months if cerebral vein thrombosis occurred due to transient factors and for
6–12 months in patients with idiopathic thrombosis and congenital “moderate”
thrombophilia.
4.1.4 Anticonvulsant therapy
The preventive use of anticonvulsants is controversial. Some studies have shown
that sensory and motor deficits, parenchymal lesions on MRI/CT, and cortical vein
thrombosis can be independent predictors of early symptomatic epileptic seizures
[26]. According to European recommendations [18], prophylactic administration of
anticonvulsants is possible for patients with local neurological deficits and foci of
parenchymal lesions. Treatment can be continued for a year. Despite the fact that
50% of patients with venous thrombosis experience brain edema, mild edema can
be relieved by isolated administration of heparin to restore venous outflow. Steroids
are not recommended for the treatment of intracranial hypertension due to their
unproven effectiveness. In severe cases, with the threat of transtentorial disloca-
tion, surgical decompression is considered the only lifesaving method of treatment.
4.2 Cardiac surgery and strokes
The incidence of strokes in the postoperative period in patients with coronary
artery bypass grafting (CABG) is about 2%, and a higher incidence of strokes is
observed in patients after valve replacement operations and other cardiac surgeries
[3]. The causes of stroke after cardiac surgery include perioperative embolism from
the aortic arch or heart chambers, systemic hypoperfusion, ischemia associated with
occlusion of large vessels, or a combination of these factors [3]. Risk factors for
stroke after cardiac surgery are old age; a history of strokes, hypertension, and
diabetes mellitus; the presence of noise in the projection of the carotid arteries; the
use of bronchodilators and diuretics; high serum creatinine levels; recovery of large
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vessels; the use of inotropes after artificial circulation; and the duration of artificial
blood circulation.
Currently, there are no special recommendations for the treatment of patients
with stroke after CABG [3]. Moreover, patients with stroke after CABG are treated
as patients with acute stroke with loading doses of aspirin (160–320 mg) [3].
4.3 Operations on the carotid arteries and strokes
Carotid endarterectomy is the standard method for treating carotid artery ste-
nosis [3]. It is recommended for 70–99% of patients with symptomatic stenosis. It is
confirmed that surgical treatment of asymptomatic stenosis reduces the risk of
ipsilateral stroke; however, the absolute advantage of this method has not been
proven. Currently, stenting is not recommended for revascularization of the carotid
arteries.
The pathophysiological mechanism of stroke in carotid revascularization may be
associated with hemodynamic cerebral ischemia or arterio-arterial embolism. The
latter mechanism may be more frequent during stenting due to endovascular access.
4.4 Acute coronary syndrome (ACS) and stroke
Intracranial hemorrhage can be a severe side effect of thrombolytic therapy in
ACS. The risk of intracranial hemorrhage depends on the previous episodes in the
history, age, and mode of thrombolytic therapy. Usually, the risk of intracranial
hemorrhage during thrombolytic therapy of acute myocardial infarction is 0.5–1%.
There are no special recommendations for the treatment of ischemic stroke in
ACS in European protocols. In the presence of ACS, the protocols of the European
Stroke Organization recommend lowering blood pressure [4, 6]. An anticoagulant
therapy is not recommended, while a combination of clopidogrel and aspirin is
recommended in terms of cardiac causes [4, 7].
4.5 Stroke in patients with atrial fibrillation
Cardio-cerebral embolism is considered to be the cause of at least 20% of ische-
mic strokes, and non-valvular AF is the most common cause, associated with a
fivefold increase in the risk of stroke, and accounts for 25% of all strokes in patients
older than 80 years [3]. Long-term thromboprophylaxis is necessary to prevent
strokes in patients with AF. Recently, for patients who cannot be treated with
warfarin and clopidogrel, it has been shown that clopidogrel and aspirin therapy
reduces the risk of vascular accidents [7]. Oral direct thrombin inhibitors such as
dabigatran have been shown to be effective in preventing stroke and systemic
embolism with a risk of intracranial hemorrhage comparable to that of warfarin.
Stroke in patients with AF can be divided into three groups:
1. Ischemic stroke in patients with insufficient therapy, i.e., not receiving
anticoagulants, despite scores on the CHADS2 scale greater than 2 [3]
2.Ischemic stroke that developed despite warfarin therapy
3.Intracranial hemorrhage that occurred in a patient receiving anticoagulants
The incidence of intracranial hemorrhage increases 7–10 times compared to
patients who do not receive oral anticoagulants and is 1.8% per year in patients at
risk of stroke [7].
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4.5.1 Treatment
In the acute phase of stroke, heparin is not recommended; its use leads to a slight
decrease in repeated strokes, an indefinite decrease in mortality, and a disability
with an increase in the frequency of intracranial hemorrhages [7].
4.6 Cerebrocardial syndrome (neurogenic stress cardiomyopathy)
The connection between the brain and the heart reflects a complex multidir-
ectional complex regulation of systemic hemodynamics and organ autoregulation of
local perfusion, which is especially pronounced in a cerebral catastrophe. Arrhyth-
mias, in particular AF, often accompany the development of stroke, while myocar-
dial infarction, Takotsubo syndrome, and sudden death are rare, although they are
also described in strokes [27–29]. Sometimes stroke patients are found to have high
levels of troponin, indicating myocardial damage.
5. Conclusion
To ensure adequate treatment, a rapid diagnosis of stroke and its nature and
cause is necessary. Specialized stroke departments allow for effective treatment and
specific therapy.
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